RocketTickers

MacroGenics Announces Positive Results from Phase 3 SOPHIA Study

Long
NASDAQ:MGNX   MacroGenics, Inc
MGNX: MacroGenics , Inc.
2019-05-15 17:07:27
MacroGenics Announces Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer - GlobeNewswire
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.